FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022081903> ?p ?o ?g. }

• W2022081903 abstract "Despite an estimated 84,000 deaths related to hepatitis C virus (HCV) infection in Europe each year, no strategy to respond to HCV is in place in the majority of European countries according to two surveys published in BMC [1-3]. Why is this so and does it matter?The lack of public interest in this important threat to public health is striking and probably explains the lack of policy responses. Hepatitis is correctly described as the silent epidemic in which patients carry the virus for decades before a quarter succumb to liver failure or liver cancer [4,5]. Most patients acquiring hepatitis C in recent decades in Europe have been infected through injecting drug use [6]. The disease therefore carries an important stigma discouraging individuals from publicly acknowledging their infection; this stigma probably also explains why patient groups are conspicuously absent. Furthermore, successful HCV treatment lacks “the Lazarus effect” seen after successful treatment of HIV. By the time symptoms of liver failure appear, HCV treatment has until recently been unable to reverse the disease. Treatment regimens have long been associated with considerable toxicity limiting access to therapy due to medical, social and structural reasons.But this scenario is rapidly changing. A paradigm shift is underway, with combinations of direct-acting antivirals replacing interferon-based therapies [7]. Treating almost every person with HCV regardless of liver disease stage, viral genotype, past therapies or comorbidities is possible. Hard-to-treat populations such as people who inject drugs, HIV-coinfected individuals and patients with psychiatric comorbidities will be much easier to treat with high cure rates. However, per-patient treatment costs will also increase and will be a challenge for national health systems due to the expanding number of patients. This will be a substantial challenge in particular for Southern and Eastern Europe, including Russia, where HCV prevalence and incidence rates are high. Even in western European countries, however, the current pricing of new direct-acting antivirals enabling interferon-free therapy – such as sofosbuvir and simeprevir – is threatening to affect healthcare budgets substantially. As a consequence, access to this beneficial therapy will be sadly limited due to conflicting economic interests.For this reason, the lack of a strategy to fight HCV is a matter of concern. In the meantime the high prices of the new drugs may prove to have the paradoxical effect of increasing public awareness of this disease, motivating policy-makers to put in place good strategies for hepatitis C prevention and treatment and bring down prices." @default.
• W2022081903 created "2016-06-24" @default.
• W2022081903 creator A5029582159 @default.
• W2022081903 creator A5062480277 @default.
• W2022081903 date "2014-09-01" @default.
• W2022081903 modified "2023-10-07" @default.
• W2022081903 title "No strategy to meet the HCV epidemic" @default.
• W2022081903 cites W1504384931 @default.
• W2022081903 cites W2032853874 @default.
• W2022081903 cites W2094963241 @default.
• W2022081903 cites W2117055822 @default.
• W2022081903 cites W2148864053 @default.
• W2022081903 doi "https://doi.org/10.1186/1471-2334-14-s6-s2" @default.
• W2022081903 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4178552" @default.
• W2022081903 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25253032" @default.
• W2022081903 hasPublicationYear "2014" @default.
• W2022081903 type Work @default.
• W2022081903 sameAs 2022081903 @default.
• W2022081903 citedByCount "6" @default.
• W2022081903 countsByYear W20220819032015 @default.
• W2022081903 countsByYear W20220819032016 @default.
• W2022081903 countsByYear W20220819032018 @default.
• W2022081903 countsByYear W20220819032021 @default.
• W2022081903 crossrefType "journal-article" @default.
• W2022081903 hasAuthorship W2022081903A5029582159 @default.
• W2022081903 hasAuthorship W2022081903A5062480277 @default.
• W2022081903 hasBestOaLocation W20220819031 @default.
• W2022081903 hasConcept C142724271 @default.
• W2022081903 hasConcept C159047783 @default.
• W2022081903 hasConcept C185032368 @default.
• W2022081903 hasConcept C190139176 @default.
• W2022081903 hasConcept C190612196 @default.
• W2022081903 hasConcept C71924100 @default.
• W2022081903 hasConceptScore W2022081903C142724271 @default.
• W2022081903 hasConceptScore W2022081903C159047783 @default.
• W2022081903 hasConceptScore W2022081903C185032368 @default.
• W2022081903 hasConceptScore W2022081903C190139176 @default.
• W2022081903 hasConceptScore W2022081903C190612196 @default.
• W2022081903 hasConceptScore W2022081903C71924100 @default.
• W2022081903 hasIssue "S6" @default.
• W2022081903 hasLocation W20220819031 @default.
• W2022081903 hasLocation W20220819032 @default.
• W2022081903 hasLocation W20220819033 @default.
• W2022081903 hasLocation W20220819034 @default.
• W2022081903 hasOpenAccess W2022081903 @default.
• W2022081903 hasPrimaryLocation W20220819031 @default.
• W2022081903 hasRelatedWork W1980075413 @default.
• W2022081903 hasRelatedWork W1997500340 @default.
• W2022081903 hasRelatedWork W2018883655 @default.
• W2022081903 hasRelatedWork W2026014464 @default.
• W2022081903 hasRelatedWork W2048190799 @default.
• W2022081903 hasRelatedWork W2060170631 @default.
• W2022081903 hasRelatedWork W2141178815 @default.
• W2022081903 hasRelatedWork W2144885503 @default.
• W2022081903 hasRelatedWork W2150494161 @default.
• W2022081903 hasRelatedWork W57099025 @default.
• W2022081903 hasVolume "14" @default.
• W2022081903 isParatext "false" @default.
• W2022081903 isRetracted "false" @default.
• W2022081903 magId "2022081903" @default.
• W2022081903 workType "article" @default.